We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Published in Primary Care

Journal Scan / Research · November 30, 2020

Long-Term Cardiovascular Safety of Febuxostat Compared With Allopurinol in Patients With Gout

The Lancet

 

Save Recommend
Share

Additional Info

The Lancet
Long-Term Cardiovascular Safety of Febuxostat Compared With Allopurinol in Patients With Gout (FAST): A Multicentre, Prospective, Randomised, Open-Label, Non-Inferiority Trial
Lancet 2020 Nov 06;[EPub Ahead of Print], IS Mackenzie, I Ford, G Nuki, J Hallas, CJ Hawkey, J Webster, SH Ralston, M Walters, M Robertson, R De Caterina, E Findlay, F Perez-Ruiz, JJV McMurray, TM MacDonald

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated